永泰生物-B(06978.HK)委任李賢秀為聯席首席科技官
格隆匯 4 月 13日丨永泰生物-B(06978.HK)宣佈,於2021年4月13日,金浩彥辭任集團聯席首席科技官之職,而李賢秀已於2021年4月13日獲委任為新任聯席首席科技官。
李賢秀分別於1985年2月及1987年2月獲韓國首爾大學頒授微生物學理學學士學位及理學碩士學位,後來於2004年10月獲韓國科學技術院頒授分子生物技術博士學位。
自1987年1月至2005年4月,李博士於韓國企業集團CJ Group製藥研究院擔任首席研究員。自2005年6月至2021年4月間,先後於韓國多家生物技術公司出任研究所所長。自2016年3月起,擔任韓國生物製藥公司AprogenInc的非執行董事。李賢秀於微生物學及生物技術方面擁有豐富的研發經驗。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.